Celsion Co. (NASDAQ:CLSN) – Stock analysts at Oppenheimer dropped their FY2022 earnings per share (EPS) estimates for Celsion in a research note issued on Thursday, August 15th. Oppenheimer analyst H. Singh now anticipates that the biotechnology company will earn $1.65 per share for the year, down from their previous forecast of $1.76. Oppenheimer also issued estimates for Celsion’s FY2023 earnings at $3.33 EPS.
Celsion (NASDAQ:CLSN) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million.
NASDAQ:CLSN opened at $1.90 on Monday. Celsion has a 52 week low of $1.35 and a 52 week high of $3.10. The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $38.93 million, a PE ratio of -2.79 and a beta of 1.94. The stock’s 50-day moving average price is $1.75 and its 200-day moving average price is $2.02.
A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. raised its position in Celsion Co. (NASDAQ:CLSN) by 5.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 146,332 shares of the biotechnology company’s stock after buying an additional 7,070 shares during the period. BlackRock Inc. owned about 0.71% of Celsion worth $267,000 at the end of the most recent reporting period. 4.73% of the stock is owned by institutional investors and hedge funds.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Read More: No Load Funds
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.